Scientific Publications
The purpose of this study was to systematically assess the prevalence, clinical consequences, and reporting of treatment-emergent hypophosphatemia within literature investigating IVI therapies marketed in the United States (US)
Authors
John Glaspy, Michelle Lim-Watson, Michael A Libre, Swagata Karkare, Nandini Hadker, Aleksandra Bajic-Lucas, William Strauss, Naomi Dahl
Journal
Therapeutics and Clinical Risk Management
View publication…
Read Now
Scientific Publications
Recent developments in digitally assisted vitreo-retinal surgery (DAVS) and heads-up setup were introduced to the global ophthalmic surgical community to enhance visualization with digital signal amplification, higher resolution, and increased depth of field, while addressing some of the ergonomic challenges associated with conventional microscopes
Authors
Leighton Morris, William Wiley, Van Sandwick, Chiraag Lathia, Hang Cheng, Dina Abulon, Nandini Hadker, Kalin Hennegan
Journal
ISPOR EU 2020
View publication…
Read Now
Scientific Publications
While technological or procedural advances have resulted in low complication and re-operation rates, there are limitations of existing technologies — including but not limited to: surgical endo-illumination challenges, need for in-procedure adjustments, and additional information/support provided by other surgical devices — all of which can create challenges for surgeons during procedures
Authors
Leighton Morris, Alan Franklin, Van Sandwick, Chiraag Lathia, Hang Cheng, Nandini Hadker, Kalin Hennegan
Journal
ISPOR EU 2020
View publication…
Read Now
Blog
Published July 6, 2021
Executive Summary
The Chinese National Reimbursement Drug List (NRDL) is managed and negotiated by the National Healthcare Security Administration (NHSA) and drugs listed on the NRDL are reimbursed by the public insurance
Since 2017, on average, a significant price discount of 44-61% was required for products to achieve a positive listing on the NRDL
Based on average 2018 sales data, products included on the 2017 NRDL were able to achieve an increase in sales revenue (188%) despite the steep average…
Read Now
Blog
Published June 2, 2021
Executive Summary
The Medical Fund Bill would increase drug spending up to 4% of the total healthcare spending in Poland
The reimbursement applications can be reviewed as quickly as 180 days, reducing the typical time-to-market of two – three years
The criteria for “innovativeness” that need to be met for inclusion on the list are still not fully fleshed out to date
Only four of the 12 candidates on the list have been approved by the Health Minister to secure reimbursement…
Read Now
Blog
Published May 25, 2021
Executive Summary
Branded novel combinations are increasingly entering the oncology market but bring a unique set of challenges to gain access and pricing success
Dynamics beyond demonstrating synergistic efficacy should be taken into consideration to optimize combination price / access outcomes
Trinity’s Take: In this article, Trinity uses select combination case studies to highlight the key elements to consider when thinking through price / access strategy for a novel combination
Evaluation of the Novel Combinations Landscape
The pursuit of a successful…
Read Now
Webinars
Available On Demand
Communicating a compelling value story to clinicians and payers is key to launching a product successfully and optimizing value throughout the product lifecycle.
But how exactly does one generate evidence that will educate stakeholders on the disease state, shape the future market and support your value narrative?
What are the ‘nuts and bolts’ of designing and conducting such studies?
How do you distill down to the key value messages from a complex data set to be most impactful to clinical…
Watch Now
Webinars
Available On Demand
A diverse workforce signals competent management for investors and is a better reflection of your customers.” – VP, Commercial Operations
TGaS Advisors, a division of Trinity Life Sciences, partnered with EMD Serono to develop Company and Pipeline Development Scorecards from a benchmark study of life sciences compared to ex-industry best practice research, including surveys/interviews with 23 unique life science companies in the TGaS Client Network. Join us to hear findings from the study.
Key Webinar Topics
Why and how does…
Watch Now
Blog
Published February 19, 2021
Written by Tom Rutkowski, Patrick Buck, Kate Watkins, and Cameron Lam…
Read Now
Webinars
Available On Demand
Are you a leader in a pre-commercial company evaluating your contract administration needs?
Are you a leader in a commercial company struggling with manual contract administration processes?
If either scenario sounds familiar, watch our latest webinar, Enabling Contract Administration Capabilities. TGaS Advisors, a division of Trinity Life Sciences, has designed this webinar specifically for Market Access and Contracting leaders in pre-commercial and emerging life science companies. During the webinar, we discuss industry best practices and approaches for building and optimizing…
Watch Now
